Crohn’s disease

June 7, 2019June 7, 2019

Mirikizumab Reduces Disease Activity in Active Crohn’s Disease, Phase 2 Trial Shows

News

Treatment with Elli Lilly’s mirikizumab led to a significant reduction in disease activity in moderate and severe Crohn’s disease patients after 12 weeks of treatment, findings from a Phase 2 ... Read more

May 22, 2019May 22, 2019

Helmsley Charitable Trust Grants $1.8 Million Toward Crohn’s Disease Research

News

The Leona M. and Harry B. Helmsley Charitable Trust has donated $1.8 million for the development of a gut-mimicking microdevice to help scientists better understand Crohn’s disease and develop new therapies. The technology ... Read more

April 29, 2019April 29, 2019

Provention Bio’s Crohn’s Disease Trial is Fully Enrolled, with Top-line Results Expected Later in Year

News

Provention Bio has completed patient enrollment for a Phase 2a clinical trial evaluating the efficacy and safety of its investigational oral therapy — PRV-6527 — for moderate to severe Crohn’s ... Read more

April 8, 2019April 8, 2019

Immunosuppressant Combo Safe, Effective for Some Older Crohn’s Patients, Trial Suggests

News

Early treatment with a combination of immunosuppressant medications may be effective and safe for older patients with Crohn’s disease, as much as it is for younger patients, data from a ... Read more

April 5, 2019April 5, 2019

EMA Advances Under-the-skin Injection of Entyvio for Crohn’s and Ulcerative Colitis

News

The European Medicines Agency (EMA) has accepted a Marketing Authorization Line Extension Application for a new subcutaneous (under-the-skin) form of Entyvio (vedolizumab). Entyvio is a biologic agent developed by Millenium ... Read more

February 15, 2019February 15, 2019

IBD Patients Have More DNA Damage in Lymphocytes, Less Vitamin B6, Study Reports

News

Patients with inflammatory bowel disease (IBD) have greater DNA damage in lymphocytes — a type of white blood cell — lower vitamin B6 and higher homocysteine levels than healthy controls, ... Read more

February 1, 2019February 1, 2019

Specific Antibodies May Be Marker of Ulcerative Colitis in Young Patients, Study Suggests

News

A positive test for the proteinase 3-anti-neutrophil cytoplasmic antibodies (PR3-ANCA) may differentiate ulcerative colitis (UC) from Crohn’s disease (CD) in children and adolescents with inflammatory bowel disease (IBD), a study suggests. The ... Read more

January 11, 2019January 11, 2019

Nominations Open for Sherman Prizes for Professional Achievement in IBD

News

Nominations are being accepted for the 2019 Sherman Prizes, which recognize trailblazing achievements in advancing patient care, medical research, public service and education in the fields of Crohn’s disease and ... Read more

December 5, 2018December 5, 2018

Potential IBD Therapy PTG-200 Safe, Well-tolerated in Healthy Volunteers, Phase 1 Results Show

News

PTG-200, being developed by Protagonist Therapeutics in collaboration with Janssen Biotech for the treatment of moderate and severe Crohn’s disease, was found safe and well-tolerated in healthy volunteers, according to top-line results of ... Read more

November 12, 2018November 12, 2018

FDA Approves Humira Biosimilar Hyrimoz for Treatment of IBD, Other Conditions

News

The U.S. Food and Drug Administration (FDA) approved Hyrimoz (adalimumab-adaz, by Sandoz), a biosimilar to AbbVie’s Humira (adalimumab) for the treatment of Crohn’s disease (CD) in adults and ulcerative colitis (UC). A biosimilar ... Read more